EA200500783A1 - Комбинация для лечения синдрома дефицита внимания с гиперактивностью - Google Patents

Комбинация для лечения синдрома дефицита внимания с гиперактивностью

Info

Publication number
EA200500783A1
EA200500783A1 EA200500783A EA200500783A EA200500783A1 EA 200500783 A1 EA200500783 A1 EA 200500783A1 EA 200500783 A EA200500783 A EA 200500783A EA 200500783 A EA200500783 A EA 200500783A EA 200500783 A1 EA200500783 A1 EA 200500783A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hyperactivity
treatment
combination
deficiency syndrome
attention deficiency
Prior art date
Application number
EA200500783A
Other languages
English (en)
Inventor
Винсент Эдвард мл. Гроппи
Эрик Джон Джэйкобсен
Джейсон Кеннет Майерс
Дэйвид Уолтер Пиотроуски
Брюс Нельсен Роджерс
Дэниел Патрик Уолкер
Донн Грегори Уишкей
Original Assignee
ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи filed Critical ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи
Publication of EA200500783A1 publication Critical patent/EA200500783A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к композициям и способам лечения СДВГ полным агонистом α7 nAChR и психостимуляторами и/или ингибиторами обратного захвата моноаминов.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200500783A 2002-12-11 2003-11-28 Комбинация для лечения синдрома дефицита внимания с гиперактивностью EA200500783A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43258602P 2002-12-11 2002-12-11
PCT/IB2003/005542 WO2004052461A1 (en) 2002-12-11 2003-11-28 Combination for the treatment of adhd

Publications (1)

Publication Number Publication Date
EA200500783A1 true EA200500783A1 (ru) 2005-12-29

Family

ID=32507968

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500783A EA200500783A1 (ru) 2002-12-11 2003-11-28 Комбинация для лечения синдрома дефицита внимания с гиперактивностью

Country Status (23)

Country Link
US (1) US20050107425A1 (ru)
EP (1) EP1572300A1 (ru)
JP (1) JP2006510663A (ru)
KR (1) KR20050085538A (ru)
CN (1) CN1735441A (ru)
AP (1) AP2005003336A0 (ru)
AU (1) AU2003283656A1 (ru)
BR (1) BR0317229A (ru)
CA (1) CA2509142A1 (ru)
CO (1) CO5700801A2 (ru)
CR (1) CR7868A (ru)
EA (1) EA200500783A1 (ru)
EC (1) ECSP055852A (ru)
HR (1) HRP20050522A2 (ru)
IS (1) IS7858A (ru)
MA (1) MA27606A1 (ru)
MX (1) MXPA05006336A (ru)
NO (1) NO20053185L (ru)
OA (1) OA12969A (ru)
PL (1) PL377552A1 (ru)
TN (1) TNSN05158A1 (ru)
WO (1) WO2004052461A1 (ru)
ZA (1) ZA200504338B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
BRPI0508771A (pt) 2004-03-25 2007-08-14 Memory Pharm Corp indazóis, benzotiazóis, benzoisotiazóis, benzisoxazóis, e a preparação e usos dos mesmos
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
JP2010522766A (ja) * 2007-03-28 2010-07-08 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー １１ベータ−ｈｓｄ１活性化合物
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
MX2010009110A (es) * 2008-02-19 2010-11-30 Adolor Corp Beloxepina, sus enantiomeros, y analogos de la misma para el tratamiento de dolor.
WO2010059618A1 (en) 2008-11-21 2010-05-27 High Point Pharmaceuticals, Llc Adamantyl benzamide compounds
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
DK3029039T3 (en) 2010-05-17 2017-12-04 Forum Pharmaceuticals Inc PHARMACEUTICAL FORMS CONTAINING CRYSTALLINIC FORMS OF (R) -7-CHLOR-N- (QUINUCLIDIN-3-YL) BENZO (B) THIOPHEN-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
WO2013169646A1 (en) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
KR102629135B1 (ko) 2021-08-19 2024-01-29 단국대학교 천안캠퍼스 산학협력단 Kds2010을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
WO2023022269A1 (ko) 2021-08-20 2023-02-23 단국대학교 천안캠퍼스 산학협력단 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
KR20230027862A (ko) 2021-08-20 2023-02-28 단국대학교 천안캠퍼스 산학협력단 주의력결핍 과잉행동장애의 진단을 위한 gat-3의 용도
KR102597711B1 (ko) 2021-08-20 2023-11-06 단국대학교 천안캠퍼스 산학협력단 Snap5114을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
AP2005003336A0 (en) 2005-06-30
CO5700801A2 (es) 2006-11-30
CA2509142A1 (en) 2004-06-24
ECSP055852A (es) 2005-09-20
IS7858A (is) 2005-05-23
EP1572300A1 (en) 2005-09-14
JP2006510663A (ja) 2006-03-30
OA12969A (en) 2006-10-13
NO20053185L (no) 2005-08-17
KR20050085538A (ko) 2005-08-29
MA27606A1 (fr) 2005-11-01
BR0317229A (pt) 2005-11-01
ZA200504338B (en) 2006-07-26
PL377552A1 (pl) 2006-02-06
US20050107425A1 (en) 2005-05-19
TNSN05158A1 (fr) 2007-05-14
WO2004052461A1 (en) 2004-06-24
NO20053185D0 (no) 2005-06-29
HRP20050522A2 (en) 2005-12-31
CR7868A (es) 2005-07-08
CN1735441A (zh) 2006-02-15
MXPA05006336A (es) 2005-08-26
AU2003283656A1 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
EA200500783A1 (ru) Комбинация для лечения синдрома дефицита внимания с гиперактивностью
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
PL372372A1 (en) Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
EA200601552A1 (ru) Замещенные конденсированные гетероциклические с-гликозиды
EA200000768A1 (ru) ЗАМЕЩЕННЫЕ ОКСОАЗАГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ ФАКТОРА Ха
EA199800620A1 (ru) Замещенные n-[(аминоиминометил или аминометил)фенил] пропиламиды
EA200400498A1 (ru) Производные фенилпиперазина как ингибиторы обратного захвата серотонина
EA200601587A1 (ru) Новые амидозамещённые гидрокси-6-фенилфенантридины
EA200100688A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОБИЦИКЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
EA200100992A1 (ru) Ингибиторы фермента impdh
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
NO20062649L (no) Biarylsulfonamider og metoder for anvendelse av disse
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
ATE421501T1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
EA200500442A1 (ru) Композиции и наборы для удаления раздражающих соединений с поверхностей тела
EA200500528A1 (ru) Пиперазинил- и диазапанилбензамиды и бензтиоамиды
ATE459353T1 (de) Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
EA200001218A1 (ru) Комбинационная терапия для лечения резистентной депрессии
ATE232191T1 (de) Verfahren und zusammensetzung zur inhibierung der polymerisierung von ethylenisch ungesättigten kohlenwasserstoffen
ATE376419T1 (de) Carbostyril-derivate mit selektiven serotonin- aufnahme inhibitoren, zur behandlung von gemütskrankheiten
EA200100517A1 (ru) Антагонисты 5ht1 для антидепрессантной терапии
ATE476982T1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
EA200801296A1 (ru) Способ лечения метаболического синдрома
EA200200948A1 (ru) Лечение псориаза